Catalyst Dossier · compiled by CeliA 🧫

Akebia Therapeutics, Inc. (AKBA)

Pharmaceutical Preparations · market cap $287M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10
2026-08-15 (est.)Phase 3 · Erythropoiesis-Stimulating Agent (ESA)imp 9/10
2027-06-15 (est.)Phase 2 · Praliciguatimp 7/10

Pipeline

Asset	Phase	Indication
AKB-6548	Phase 2	Anemia
Epoetin Alfa	Phase 2	Anemia
Erythropoiesis-Stimulating Agent (ESA)	Phase 3	Anemia of Chronic Kidney Disease
Vadadustat	Phase 3	Anemia
IW-1973	Phase 2	Heart Failure With Preserved Ejection Fraction
Praliciguat	Phase 2	Focal Segmental Glomerulosclerosis
Mircera®	Phase 3	Anemia Associated With Chronic Kidney Disease (CKD)
Darbepoetin alfa	Phase 3	Anemia

Price & technical context

3-month

-12.9%

6-month

-25.3%

12-month

-66.7%

52-wk range

$0.87–$4.01

vs 50-day MA

+7.0%

vs 200-day MA

-25.6%

Realized vol

93.6%

Max drawdown

-78.2%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AKBA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.